ABC | Volume 113, Nº5, Novembro 2019

Artigo de Revisão Fernandes et al Doenças de depósito e hipertrofia ventricular Arq Bras Cardiol. 2019; 113(5):979-987 9. González-López E, Gallego-Delgado M, Guzzo-Merello G, de Haro- Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585-94. 10. Mohammed SF, Mirzoyev SA, Edwards WD, Dogan A, Grogan DR, Dunlay SM, et al. Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction. JACC Heart Fail. 2014;2(2):113-22. 11. MaurerMS, HannaM, GroganM, Dispenzieri A,Witteles R, Drachman B, et al. Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey); THAOS Investigators. J Am Coll Cardiol. 2016;68(2):161-72. 12. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, et al. Systemic cardiac amyloidoses:diseaseprofilesandclinicalcourses of the 3maintypes. Circulation. 2009;120(13):1203-12. 13. Nietlispach F, Webb JG, Ye J, Cheung A, Lichtenstein SV, Carere RG, et al. Pathology of transcatheter valve therapy. JACC Cardiovasc Interv. 2012;5(5):582–90. 14. Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, et al. Occult transthyretin cardiac amyloid in severe calcific aortic stenosis: prevalence and prognosis in patients undergoing surgical aortic valve replacement. Circ Cardiovasc Imaging. 2016;9(8). pii: e005066. 15. Lamke GT, Allen RD, Edwards WD, Tazelaar HD, Danielson GK. Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy. A study of 204 cases (1996-2000). Cardiovasc Pathol. 2003;12(3):149–58. 16. Helder MR, Schaff HV, Nishimura RA, Gersh BJ, Dearani JA, Ommen SR, et al. Impact of incidental amyloidosis on the prognosis of patients with hypertrophic cardiomyopathy undergoing septal myectomy for left ventricular outflow tract obstruction. Am J Cardiol. 2014;114(9):1396–9. 17. Damy T, Costes B, Hagège AA, Donal E, Eicher JC, SlamaM, et al. Prevalence and clinical phenotype of hereditary transthyretin amyloid cardiomyopathy in patients with increased left ventricular wall thickness. Eur Heart J. 2016;37(23):1826-34. 18. Phelan D, Collier P , Thavendiranathan P , Popović ZB, Hanna M, Plana JC, et al. R elative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442-8. 19. Fontana M, Pica S, Reant P , Abdel-Gadir A, Treibel TA, Banypersad SM. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015;132(16):1570-9. 20. Clesham GJ, Vigushin DM, Hawkins PN, Pepys MB, Oakley CM, Nihoyannopoulos P. Echocardiographic assessment of cardiac involvement in systemic AL amyloidosis in relation to whole body amyloid load measured by serum amyloid P component (SAP) clearance. Am J Cardiol. 1997;80(8):1104-8. 21. HongoM, IkedaS.Echocardiographicassessmentoftheevolutionofamyloid heart disease: a study with familial amyloid polyneuropathy. Circulation. 1986;73(2):249-56. 22. Mesquita ET, Jorge AJL, Souza CV Junior, Andrade TR. Cardiac amyloidosis and its newclinical phenotype: heart failurewith preserved ejection fraction. Arq Bras Cardiol. 2017;109(1):71-8. 23. Appleton CP, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. J Am Coll Cardiol. 1988;12(2):426-40. 24. Appleton CP, Hatle LK, Popp RL. Demonstration of restrictive ventricular physiology by Doppler echocardiography. J Am Coll Cardiol. 1988;11(4):757-68. 25. Sun JP, Stewart WJ, Yang XS, Donnell RO, Leon AR, Felner JM, et al. Differentiation of hypertrophic cardiomyopathy and cardiac amyloidosis from other causes of ventricular wall thickening by two-dimensional strain imaging echocardiography. Am J Cardiol. 2009;103(3):411-5. 26. Martinez-NaharroA, TreibelTA, Abdel-GadirA, BulluckH, ZumboG , Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. J AmColl Cardiol. 2017;70(4):466-77. 27. Desnick RJ, Joannou YA, Eng CM. Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D(eds). The metabolic bases of inherited disease. 8 th ed. New York:Mac Graw-Hill;2001.p.3733-74. 28. Branton MH, Schiffmann R, Sabnis SG, Murray GJ, Quirk JM, Altarescu G, et al. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore). 2002;81(2):122-38. 29. Bishop DF, Kornreich R, Desnick RJ. Structural organization of the human alpha-galactosidase A gene: further evidence for the absence of a 3’ untranslated region. Proc Natl Acad Sci USA. 1988;85(11):3903-7. 30. Mehta A, Ricci R,Widmer U, Dehout F , Garcia de Lorenzo A, Kampmann C, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest. 2004;34(3):236-42. 31. Desnick RJ , Brady R, Barranger J, Collins AJ, Germain DP , Goldman M, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138(4):338-46. 32. Weidemann F, Breunig F, Beer M, Sandstede J, Turschner O, Voelker W, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation. 2003;108(11):1299-301. 33. Spinelli L, Pisani A, M Sabbatini, Petretta M, Andreucci MV, Procaccini D, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry’s disease. Clin Genet. 2004;66(2):158-65. 34. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, Elliott PM. Prevalence of Anderson-Fabry disease in male patients with late-onset hypertrophic cardiomyopathy. Circulation. 2002;105(12):1407-11. 35. Morita H, Larson MG, Barr SC, Vasan RS, O’Donnell CJ, Hirschhorn JN, et al. Monogenic mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation. 2006;113(23):2697-705. 36. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart. 2003;89(8):929-30. 37. Linhart A, Palecek T, Bultas J, Ferguson JJ, Hrudová J , Karetová D, et al . New insights in cardiac structural changes in patients with Fabry’s disease. Am Heart J. 2000;139(6):1101–8. 38. O’Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52(4):326-35. 39. Kampmann C, Linhart A, Baehner F, Palecek T , Wiethoff CM, Miebach E, et al. Start and progression of Anderson-Fabry disease-related cardiomyopathy. Int J Cardiol. 2008;130(3):367-73. 40. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and disease impact in a cohort of 98 hemizygous males. J Med Genet. 2001;38(11):750-60. 41. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and disease impact in a cohort of 60 obligated female patients. J Med Genet. 2001;38(11):769-75. 42. Niemann M, Breunig F, Beer M, Herrmann S, Strotmann J , Hu K, Emmert A, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart. 2010;96(23):1915-9. 43. Wu JC, Ho CY, Skali H, Abichandani R, Wilcox WR, Banikazemi M, et al. Cardiovascular manifestations of Fabry’s disease: relationships between left ventricular hypertrophy, disease severity and alpha-galactosidase A activity. Eur Heart J. 2010;31(9):1088-97. 44. Pieroni M, C Chimenti, De Cobelli F, Morgante E, Del Maschio A, Gaudio C, et al. Fabry disease cardiomyopathy: echocardiographic detection of endomyocardialglycosphingolipidcompartmentalization. JAmCollCardiol. 2006;47(8):1663-71. 986